SAMJIN PHARMACEUTICAL CO.,LTD
Financials
Valuation Metrics
SAMJIN PHARMACEUTICAL CO.,LTD's Market Cap is ₩2579B. At end of 2025 it was ₩2631B. Ranked #681 of 2,410 in KR market (top 28%), #398 of 779 on KOSPI (top 51%), #72 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 31%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 257.88B KRW | KR#681/2,410 Sec#72/231 |
| Revenue | 311.37B KRW | KR#812/2,410 Sec#37/231 |
| Net Income | 23.26B KRW | KR#649/2,410 Sec#41/231 |
| Total Assets | 476.87B KRW | KR#791/2,410 Sec#47/231 |
| Net Assets | 298.77B KRW | KR#721/2,410 Sec#48/231 |
| Employees | 809 | KR#310/2,410 Sec#27/231 |
| Value | ||
| P/E | 11.09x | KR#926/2,410 Sec#48/231 |
| P/B | 0.86x | KR#1,409/2,410 Sec#87/231 |
| PEG | 0.62x | KR#725/2,410 Sec#46/231 |
| P/S | 0.83x | KR#1,322/2,410 Sec#73/231 |
| EV/EBITDA | 15.12x | KR#911/2,410 Sec#53/231 |
| FCF Yield | 8.71% | KR#695/2,410 Sec#34/231 |
| Profitability | ||
| ROE | 7.79% | KR#811/2,410 Sec#54/231 |
| ROA | 4.88% | KR#757/2,410 Sec#60/231 |
| Op. Margin | 7.94% | KR#662/2,410 Sec#54/231 |
| Revenue Growth | 0.28% | KR#1,508/2,410 Sec#151/231 |
| Earnings Growth | 17.82% | KR#710/2,410 Sec#47/231 |
| Financial Health | ||
| Debt Ratio | 59.61% | KR#1,084/2,410 Sec#127/231 |
| Total Debt | 129.00B KRW | KR#648/2,410 Sec#38/231 |
| FCF | 22.47B KRW | KR#485/2,410 Sec#28/231 |
| Cash | 12.80B KRW | KR#1,549/2,410 Sec#127/231 |
| Current Ratio | 1.32x | KR#1,354/2,410 Sec#144/231 |
| Net Debt/EBITDA | 4.70x | KR#1,009/2,410 Sec#75/231 |
| Dividend | ||
| Div. Yield | 4.11% | KR#450/2,410 Sec#16/231 |
| Div. Growth | 0.00% | KR—/2,410 Sec—/231 |
| Performance | ||
| 1Y Return | -1.88% | KR#618/2,410 Sec#34/231 |
| 1M Return | 1.47% | KR#253/2,410 Sec#29/231 |
| From 52W High | -25.25% | KR#301/2,410 Sec#19/231 |
| 1Y MDD | -31.13% | KR#268/2,410 Sec#17/231 |
| Trading | ||
| Volume | 24,425 shares | KR#1,419/2,410 Sec#144/231 |
| Trading Value | 470.2M KRW | KR#838/2,410 Sec#87/231 |
| Foreign Own. | 3.68% | KR#1,120/2,410 Sec#104/231 |
| Per Share | ||
| EPS | 1,746 KRW | KR#490/2,410 Sec#31/231 |
| BPS | 22,430 KRW | KR#493/2,410 Sec#34/231 |
Company Info
Samjin Pharmaceutical, established in 1968, manufactures and sells pharmaceuticals, boasting a diverse portfolio that includes Gabol tablets and Plaless tablets. The company is expanding its business into health functional foods, cosmetics, and medical devices, with a strong focus on developing new drugs for conditions such as cancer and dementia. Following the completion of an EU-GMP-grade injectable line at its Osong raw material synthesis plant in 2022, Samjin Pharmaceutical is boosting production and facility investments for global growth. Samjin Pharmaceutical is headquartered in Mapo-gu, Seoul.